Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432093 · ClinicalTrials.gov registry record · NA
Intensive Glycemic Management and Outcomes Following Liver Transplantation
A NA study of Hospital Hyperglycemia and Post-transplant Hyperglycemia, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT01432093: Completed NA study of Hospital Hyperglycemia and Post-transplant Hyperglycemia, sponsored by Mayo Clinic.
NCT01432093 is a NA study of Hospital Hyperglycemia and Post-transplant Hyperglycemia that has completed, run by Mayo Clinic. The registered enrollment target is 270 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432093, a NA study of Hospital Hyperglycemia and Post-transplant Hyperglycemia, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
Most people develop high blood sugars following liver transplant that requires treatment with insulin in the hospital, even if they don't have diabetes, due to stress and use of steroid medications. High blood sugar levels can be treated with a hormone that the body makes called insulin. This study is being done to determine if maintaining normal blood sugar levels after transplant for as long as needed while in the hospital results in a lesser incidence of death, infections, transplanted liver rejection or failure or need for rehospitalization within 90 days after transplant.
Primary Outcome
The primary outcome is a 90 day composite of mortality by any cause, graft failure, rejection, infections, and rehospitalization following liver transplantation.
Conditions Studied
Interventions
- OTHER Intensive glycemic management
- OTHER Conventional management
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-07 |
| Phase | NA |
What the finished NCT01432093 record still lists
NCT01432093 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Hospital Hyperglycemia appearing as the primary indexed condition, and to 2 interventions - of which Intensive glycemic management is the first listed.
NCT01432093 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01432093 about?
NCT01432093 is a clinical study titled "Intensive Glycemic Management and Outcomes Following Liver Transplantation". Most people develop high blood sugars following liver transplant that requires treatment with insulin in the hospital, even if they don't have diabetes, due to stress and use of steroid medications. High blood sugar levels can be treated with a hormone that the body makes called insulin. This study ...
What is the current status of trial NCT01432093?
This trial is currently completed. It is a NA study. The enrollment target is 270 participants. The study started on 2011-10. Estimated completion is 2013-07.
What conditions does trial NCT01432093 study?
This clinical trial studies the following conditions: Hospital Hyperglycemia, Post-transplant Hyperglycemia.
What interventions are being tested in trial NCT01432093?
The interventions under investigation include: Intensive glycemic management (OTHER), Conventional management (OTHER).
Who is sponsoring clinical trial NCT01432093?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01432093 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01432093's enrollment target sits among peer trials
270 387th of 2000 higher than 1,609 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia